Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

Premier Diagnostic Health Services Q1 loss increases

Premier Diagnostic Health Services Inc. has reported that loss and comprehensive loss for the first quarter ended December 31, 2013 was C$201,626, compared to loss and comprehensive loss of C$99,337 for the same quarter ended December 31, 2012.

Published By MarketLine
23 Apr 2014
NewsWire
NewsWire

Capital Region selects Patientco's cloud-based payment automation solution

Capital Region Medical Center, a community-based hospital and an affiliate of the University of Missouri Health Care System, has selected Patientco, a revenue cycle management software company, for its cloud-based patient payment automation solution.

Published By MarketLine
23 Apr 2014
NewsWire
NewsWire

Gilead Sciences reports higher Q1 net income, reiterates guidance for 2014

Gilead Sciences, Inc., a biopharmaceutical company, has reported a net income attributable to the company of $2.23 billion, or $1.33 per diluted share, for the first quarter ended March 31, 2014, compared to $722.19 million, or $0.43 per diluted share, for the same quarter ended March 31, 2013. For 2014, the company has reiterated its net product sales guidance range of $11.3 billion to $11.5 billion.

Published By MarketLine
23 Apr 2014
NewsWire
NewsWire

Boston Scientific implants first patient in heart failure trial

Boston Scientific Corporation, a medical device company, has implanted first patient in a clinical trial of the next generation ACUITY X4 left-ventricular, or LV, pacing leads and RELIANCE 4-FRONT defibrillation, or ICD, leads in patients with cardiac arrest or heart failure.

Published By MarketLine
23 Apr 2014
NewsWire
NewsWire

Bristol-Myers expands manufacturing agreement with Samsung BioLogics

Bristol-Myers Squibb Company and Samsung BioLogics have announced the expansion of their existing manufacturing agreement in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at its Incheon manufacturing site.

Published By MarketLine
23 Apr 2014
NewsWire
NewsWire

GlaxoSmithKline and Theravance initiate Phase III COPD study

GlaxoSmithKline, or GSK, and Theravance, Inc., a biopharmaceutical company, have initiated a Phase III efficacy and safety study of a combination treatment of the inhaled corticosteroid, or ICS, fluticasone furoate and long-acting beta2 agonist, or LABA, vilanterol, or FF/VI.

Published By MarketLine
23 Apr 2014
NewsWire
NewsWire

Amgen reports lower Q1 net income, provides outlook for 2014

Amgen Inc., a biotechnology company, has reported a net income of $1.07 billion, or $1.40 per diluted share, for the first quarter ended March 31, 2014, compared to $1.43 billion, or $1.88 per diluted share, for the same quarter ended March 31, 2013. For 2014, the company expects total revenues to be in the range of $19.2 billion to $19.6 billion and adjusted EPS to be in the range of $7.90 to $8.20.

Published By MarketLine
23 Apr 2014
NewsWire
NewsWire

Centene reports higher Q1 profit, provides outlook for 2014

Centene Corporation, a provider of health insurance solutions, has reported net earnings attributable to common shareholders of $32.98 million, or $0.56 per diluted share, for the first quarter ended March 31, 2014, compared to $23 million, or $0.42 per diluted share, for the same quarter ended March 31, 2013. For 2014, the company expects diluted EPS to be in the range of $3.60 to $3.90.

Published By MarketLine
23 Apr 2014
NewsWire
NewsWire

REGENX and AveXis sign licensing agreement to develop treatment of SMA

REGENX Biosciences, LLC, a biotechnology company and AveXis, Inc. have entered into an exclusive licensing agreement for the development and commercialization of products to treat spinal muscular atrophy, or SMA, using NAV rAAV9 vectors.

Published By MarketLine
23 Apr 2014
NewsWire
NewsWire

GENEWIZ unveils new pharmacogenomics test

GENEWIZ, Inc., a genomics service provider, has unveiled PGxOne, a new pharmacogenomics test that reportedly provides clinically relevant data for personalized patient treatment.

Published By MarketLine
23 Apr 2014

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.